<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17895897</article-id><article-id pub-id-type="pmc">2360439</article-id><article-id pub-id-type="pii">6603988</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Barone</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Nuzzo</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cassano</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Basso</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schinzari</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giuliante</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>D'Argento</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Trigila</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Astone</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pozzo</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Unit of Medical Oncology, Department of Internal Medicine, Catholic University of Sacred Heart</institution> Rome, <country>Italy</country></aff><aff id="aff2"><label>2</label><institution>Unit of Hepatobiliary Surgery, Department of General Surgery, Catholic University of Sacred Heart</institution> Rome, <country>Italy</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:carlobarone@rm.unicatt.it">carlobarone@rm.unicatt.it</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>09</month><year>2007</year></pub-date><pub-date pub-type="collection"><day>16</day><month>10</month><year>2007</year></pub-date><pub-date pub-type="ppub"><day>22</day><month>10</month><year>2007</year></pub-date><volume>97</volume><issue>8</issue><fpage>1035</fpage><lpage>1039</lpage><history><date date-type="received"><day>16</day><month>05</month><year>2007</year></date><date date-type="rev-recd"><day>27</day><month>07</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>08</month><year>2007</year></date></history><copyright-statement>Copyright 2007, Cancer Research UK</copyright-statement><copyright-year>2007</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of these patients. Forty patients received modified FOLFIRI: irinotecan 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, day 1; folinic acid, 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>; and 5-fluorouracil: as a 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> bolus, days 1 and 2, and a 48-h continuous infusion 1200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, from day 1. Treatment was repeated every 2 weeks, with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen (47.5&#x00025;) of 40 patients achieved an objective response; 13 (33&#x00025;) underwent resection. After a median follow-up of 56 months, median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times.</p></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>irinotecan</kwd><kwd>FOLFIRI</kwd><kwd>liver metastases</kwd><kwd>neoadjuvant</kwd></kwd-group></article-meta></front><body><p>Worldwide, colorectal cancer (CRC) is the fourth most common malignancy in men and the third most common in women. In 2002, the disease accounted for more than one million new cancer cases and caused 528&#x02009;978 deaths (<xref ref-type="other" rid="bib20">Parkin <italic>et al</italic>, 2005</xref>). Approximately 25&#x00025; of CRC patients present with metastatic disease, with the liver being the most common site of metastasis. Over time, 40&#x02013;50&#x00025; of newly diagnosed CRC patients will develop metastatic disease (<xref ref-type="other" rid="bib25">Saltz <italic>et al</italic>, 2000</xref>). The 5-year survival rate for patients with metastatic CRC (mCRC) is 5&#x02013;30&#x00025; (<xref ref-type="other" rid="bib30">Van Cutsem <italic>et al</italic>, 2005</xref>).</p><p>Patients who are able to undergo resection of isolated liver metastases have the chance of cure or improved survival. If cases are carefully selected for surgery, the 5-year survival rate may be as high as 60&#x00025; (<xref ref-type="other" rid="bib9">Fernandez <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib21">Pawlik <italic>et al</italic>, 2005</xref>). However, only 10&#x02013;20&#x00025; of patients with mCRC are suitable for liver resection at presentation (<xref ref-type="other" rid="bib1">Adam, 2003</xref>). Over the last 10 years, the introduction of two new active cytotoxic chemotherapy drugs and several targeted biological agents has improved the outlook for patients with mCRC. Median survival times in excess of 20 months can now be expected with the first- and second-line use of irinotecan and&#x0002f;or oxaliplatin in combination with 5-fluorouracil (5-FU)&#x0002f;folinic acid (FA). This compares favourably with the 12&#x02013;14 months previously achieved with 5-FU&#x0002f;FA alone (<xref ref-type="other" rid="bib7">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib27">Thirion <italic>et al</italic>, 2004</xref>).</p><p>These more active chemotherapy regimens are also associated with higher response rates of 39&#x02013;62&#x00025; (<xref ref-type="other" rid="bib6">Bismuth <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib7">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib25">Saltz <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib28">Tournigand <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib5">Alberts <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib17">Kohne <italic>et al</italic>, 2005</xref>). In addition, as many as 68&#x00025; of responding patients with initially unresectable liver disease have been reported to be subsequently eligible for secondary resection of their metastases (<xref ref-type="other" rid="bib5">Alberts <italic>et al</italic>, 2005</xref>). Indeed, the importance of maximising response rates in this setting was highlighted by the retrospective analysis of <xref ref-type="other" rid="bib11">Folprecht <italic>et al</italic> (2005</xref>), which demonstrated a strong correlation between response and resection rates, especially in selected patients with no disease outside the liver.</p><p>The present study previously reported that 32.7&#x00025; of patients with CRC were able to undergo potentially curative surgical resection of initially unresectable liver metastases following neoadjuvant chemotherapy with an irinotecan&#x0002f;5-FU&#x0002f;FA combination (modified FOLFIRI) (<xref ref-type="other" rid="bib22">Pozzo <italic>et al</italic>, 2004</xref>). This paper reports on the long-term follow-up of these patients, providing data on overall survival, disease-free (DF) survival and time to progression (TTP).</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patients</title><p>Patients aged 18&#x02013;75 years with unresectable colorectal liver metastases were eligible for entry into the study. Other eligibility criteria were no evidence of extrahepatic disease or involvement of more than 70&#x00025; of the liver; Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; no previous chemotherapy for advanced disease; any adjuvant chemotherapy completed at least 6 months prior to study entry; no history of other malignancies; adequate bone marrow (WBC &#x0003e;3 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>, platelets &#x0003e;100 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>, haemoglobin &#x0003e;10&#x02009;g&#x02009;dl<sup>&#x02212;1</sup>), liver (total bilirubin &#x0003c;2&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>, aspartate aminotransferase or alanine aminotransferase &#x0003c;3 &#x000d7; upper limit of normal) and renal function (blood urea nitrogen &#x02a7d;30&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>, creatinine clearance &#x0003e;60&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, serum creatinine &#x02a7d;1.5&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>); and a life expectancy of more than 3 months. Written informed consent was provided by all patients.</p></sec><sec><title>Chemotherapy</title><p>Modified FOLFIRI was administered every 2 weeks and consisted of the following: irinotecan 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> given i.v. on day 1; 5-FU 1200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> continuous i.v. infusion over 48&#x02009;h from day 1; FA 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> i.v. on days 1 and 2 and 5-FU 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> i.v. bolus on days 1 and 2. Response was assessed every 12 weeks (six cycles). In cases of neutropaenia (&#x02a7d;1.5 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>), thrombocytopaenia (&#x02a7d;100 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>) or significant non-haematologic toxicity, treatment was delayed for 1 week. In the event of grade 3&#x0002f;4 neutropaenia or diarrhoea, the doses of irinotecan and 5-FU were reduced by 25&#x00025;. The dose of 5-FU only was similarly reduced in the event of grade 3&#x0002f;4 stomatitis. Treatment was interrupted for grade 4 haematologic toxicity or grade 4 gastrointestinal toxicity (lasting &#x0003e;1 week after a previous dose reduction or a delay in dose administration of &#x0003e;2 weeks).</p><p>Chemotherapy was continued until an objective response was achieved (indicating suitability for surgery), or until disease progression or unacceptable toxicity. Those patients who underwent resection of their liver metastases received six further cycles of the same chemotherapy regimen postoperatively. Patients with progressive disease were treated at the discretion of the investigator.</p></sec><sec><title>Assessments</title><p>Initial unresectability of liver metastases was assessed as described previously, using the criteria set out by the institution at which the study was carried out (<xref ref-type="other" rid="bib22">Pozzo <italic>et al</italic>, 2004</xref>).</p></sec></sec><sec><title>RESULTS</title><sec><title>Patients</title><p>Forty patients were enrolled into the study over 2.5 years up to January 2003. The patients' baseline characteristics are outlined in <xref rid="tbl1" ref-type="table">Table 1</xref>. The median age of the patients was 58.7 years (range: 32&#x02013;75 years) and the majority were male (60&#x00025;). All but one patient had an ECOG performance status of 0. The majority of patients (67.5&#x00025;) had synchronous metastases, with the remainder being metachronous. At study entry, 21 patients (52.5&#x00025;) had less than three metastases and 11 (27.5&#x00025;) had more than six. Twelve (30&#x00025;) patients had at least one lesion &#x02a7e;5&#x02009;cm in diameter and seven (17.5&#x00025;) patients had metastases that were unfavourably located in the hilum.</p><p>Of those patients with liver metastases that were considered to be unresectable, 35&#x00025; had large numbers of metastases, 25&#x00025; had large metastases, 5&#x00025; had inadequate liver reserve and 35&#x00025; had surgically inaccessible metastases (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p></sec><sec><title>Response to chemotherapy</title><p>As of December 10 2006, median follow-up was 56 months. All 40 patients had been evaluated for response yielding an objective response rate of 47.5&#x00025;, including two complete responses. Of the 19 (47.5&#x00025;) patients who experienced an overall response, 16 were considered to be eligible for surgery (after a median of eight cycles of chemotherapy per patient (range: 6&#x02013;12)) and 13 underwent resection of their liver metastases. The median overall survival of these patients has not yet been reached. The median survival for all 40 patients was 31.5 months (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and in non-resected patients, 24 months (<xref rid="tbl2" ref-type="table">Table 2</xref>). Nine out of 40 patients (22.5&#x00025; (95&#x00025; CI: 10.5&#x02013;34.5&#x00025;)) were still alive, including one not resected patient. The median TTP for all patients was 14.3 months (range: 2&#x02013;49), and in non-resected patients, 5.2 months.</p></sec><sec><title>Adverse events</title><p>The treatment was well tolerated and the adverse events that were observed and described previously were those typical of the cytotoxic agents used (<xref ref-type="other" rid="bib22">Pozzo <italic>et al</italic>, 2004</xref>). There were no delayed onset adverse events. There were no significant differences in the incidence and severity of adverse events experienced by patients during the additional postresection chemotherapy phase compared with those reported for the initial phase of treatment.</p></sec><sec><title>Surgery</title><p>Among the 13 patients who underwent surgery, there were 13 R0 liver resections. Most of these patients (10 out of 13) underwent multiple segmental resections. As reported previously, the resection rate following chemotherapy was highest in those patients with large (&#x0003e;5&#x02009;cm) metastases (6 out of 10) (<xref ref-type="other" rid="bib22">Pozzo <italic>et al</italic>, 2004</xref>). Also, there was no postoperative mortality in the 2 months following surgery. One patient experienced anaemia as a consequence of postoperative bleeding (<xref ref-type="other" rid="bib22">Pozzo <italic>et al</italic>, 2004</xref>).</p></sec><sec><title>Disease-free survival</title><p>The median DF survival of the resected patients was 52.5 months (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). At the time of reporting, a median of 56 months from resection, 6 (46&#x00025; (95&#x00025; CI: 19.3&#x02013;72.9&#x00025;)) of the 13 radically resected patients were still disease free and 8 (62&#x00025;) of the 13 were still alive (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p></sec></sec><sec><title>DISCUSSION</title><p>After a median follow-up period of nearly 60 months, the median survival for all patients was 31.5 months. This is one of the highest reported median survival times for a prospective study in similar groups of patients treated with standard combinations of cytotoxic agents. Moreover, currently, the median survival time for those patients who underwent secondary resections of their liver metastases has not yet been reached.</p><p>It has been recognised for some time that resection of liver metastases offers the best long-term hope for patients with mCRC. Chemotherapy regimens combining 5-FU&#x0002f;FA with irinotecan and&#x0002f;or oxaliplatin have demonstrated impressive efficacy in the downstaging of liver metastases to permit secondary resection (<xref ref-type="other" rid="bib30">Van Cutsem <italic>et al</italic>, 2005</xref>) and their role in the neoadjuvant setting is now essentially undisputed. However, as yet, there is no consensus about which neoadjuvant regimen will be the most effective, either in general terms or for particular patients (as defined by disease or genotypic variation). Emerging data suggest that the addition of targeted biological agents to such regimens will further improve efficacy. Indeed, <xref ref-type="other" rid="bib12">Folprecht <italic>et al</italic> (2006)</xref> reported a median survival time of 33 months, using cetuximab, an EGFR-targeted monoclonal antibody, in combination with irinotecan&#x0002f;5-FU&#x0002f;FA. In a randomised phase III trial, cetuximab was shown to increase response rate, progression-free survival and resection rate over FOLFIRI alone in patients with advanced CRC, with the PFS benefit being greatest for those patients with liver-only metastases (<xref ref-type="other" rid="bib29">Van Cutsem <italic>et al</italic>, 2007</xref>).</p><p>One of the factors that have hindered comparisons between studies of neoadjuvant treatment of initially unresectable colorectal liver metastases is that there is no universally accepted definition of unresectability. Patient selection is a crucial factor, both for maximising the benefits achievable from primary resection (<xref ref-type="other" rid="bib13">Fong <italic>et al</italic>, 1999</xref>) and for enabling the highest resection rates following neoadjuvant therapy (<xref ref-type="other" rid="bib2">Adam <italic>et al</italic>, 2004a</xref>, <xref ref-type="other" rid="bib3">2004b</xref>; <xref ref-type="other" rid="bib11">Folprecht <italic>et al</italic>, 2005</xref>). In their retrospective analysis, <xref ref-type="other" rid="bib11">Folprecht <italic>et al</italic> (2005)</xref> found that in studies which enrolled patients with metastases confined to the liver, 24&#x02013;54&#x00025; of patients were able to undergo resection of their metastases subsequent to chemotherapy, whereas only 1&#x02013;26&#x00025; of patients in non-selective trials (patients with hepatic or extrahepatic disease) became eligible for secondary surgery. However, this analysis found a strong correlation between the response rate to neoadjuvant therapy and the resection rate in both the selected (<italic>r</italic>&#x0003d;0.96, <italic>P</italic>&#x0003d;0.002) and unselected (<italic>r</italic>&#x0003d;0.74, <italic>P</italic>&#x0003c;0.001) patients.</p><p>Studies of resection following neoadjuvant therapy have also demonstrated long-term benefits. <xref ref-type="other" rid="bib14">Giacchetti <italic>et al</italic> (1999)</xref> reported that 77 out of 151 (51&#x00025;) patients had surgery with curative intent following neoadjuvant treatment with 5-FU&#x0002f;FA&#x0002f;oxaliplatin. Complete resection was achieved in 58 patients. The median survival of the operated patients was 48 months (range: 25&#x02013;71), and the 5-year survival rate was 50&#x00025; (range: 38&#x02013;61). A more recent retrospective analysis by <xref ref-type="other" rid="bib31">Zaniboni <italic>et al</italic> (2005)</xref> of oxaliplatin-based chemotherapy found an overall response rate of 78.5&#x00025; in 105 patients. Ninety-nine patients had liver surgery, with 79&#x00025; undergoing radical resection. The median survival time for these patients was 42 months.</p><p>In a study using a neoadjuvant combination of 5-FU&#x0002f;FA&#x0002f;irinotecan&#x0002f;oxaliplatin (FOLFOXIRI) (<xref ref-type="other" rid="bib18">Masi <italic>et al</italic>, 2006</xref>), there was a response rate of 72&#x00025; in unselected patients and a 26&#x00025; (19 patients) hepatic resection rate. In five patients, extrahepatic disease was also resected. The median overall survival of surgical patients was 36.8 months, with a 4-year survival rate of 37&#x00025;. The overall survival of patients who responded to chemotherapy but did not undergo surgery was 22.2 months (<italic>P</italic>&#x0003d;0.0114). In a randomised phase III trial, FOLFOXIRI improved response rate, progression-free and overall survival compared with FOLFIRI, with secondary R0 resection rates of 15 <italic>vs</italic> 6&#x00025; in non-selected patients and 36 <italic>vs</italic> 12&#x00025; in patients with metastases confined to the liver (<xref ref-type="other" rid="bib8">Falcone <italic>et al</italic>, 2007</xref>).</p><p>A multicentre phase II study investigated the use of irinotecan with 5-FU&#x0002f;FA (FOLFIRI) as neoadjuvant chemotherapy in selected patients with unresectable liver metastases (<xref ref-type="other" rid="bib15">Ho <italic>et al</italic>, 2005</xref>). The overall response rate was 55&#x00025; (22 out of 40 patients: 95&#x00025; CI: 39.5&#x02013;70.4&#x00025;). Median overall survival was 20 months (95&#x00025; CI: 17.7&#x02013;26.6). Four patients underwent resection of metastases and remained alive at a median follow-up time of 33 months.</p><p>In the current study, neoadjuvant treatment with FOLFIRI achieved a response rate of 47.5&#x00025;, with one-third of patients able to undergo secondary resection of liver metastases. Following resection, patients achieved a worthwhile median DF survival of 52.5 months. Median survival (all patients) was 31.5 months after a median follow-up of 56.0 months, and will be higher in radically resected patients, the median survival not yet having been reached. This compares favourably with <xref ref-type="other" rid="bib15">Ho <italic>et al</italic> (2005)</xref> and other phase II studies in patients with initially unresectable metastases confined to the liver (<xref ref-type="other" rid="bib11">Folprecht <italic>et al</italic>, 2005</xref>) and confirms the benefit of perioperative chemotherapy demonstrated in the EORTC EPOC trial in patients with resectable liver metastases (<xref ref-type="other" rid="bib19">Nordlinger <italic>et al</italic>, 2007</xref>). Furthermore, the median overall survival is approaching twice that for unselected, unresected patients reported for combination therapy in the FOCUS (<xref ref-type="other" rid="bib26">Seymour <italic>et al</italic>, 2007</xref>) and CAIRO trials (<xref ref-type="other" rid="bib23">Punt <italic>et al</italic>, 2007</xref>).</p><p>As the use of neoadjuvant therapy has increased, so has the concern about possible long-term adverse effects of chemotherapy, particularly on the liver, where there is some evidence of vascular changes (<xref ref-type="other" rid="bib24">Rubbia-Brandt <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib4">Adam <italic>et al</italic>, 2005</xref>) and steatohepatitis (<xref ref-type="other" rid="bib10">Fernandez <italic>et al</italic>, 2005</xref>) following chemotherapy. However, although the vascular changes may increase the risk of intraoperative bleeding, it is not thought that they have any significant clinical impact (<xref ref-type="other" rid="bib4">Adam <italic>et al</italic>, 2005</xref>).</p><p>Also, a retrospective study by <xref ref-type="other" rid="bib16">Karoui <italic>et al</italic> (2006)</xref> showed that although preoperative chemotherapy was significantly associated with sinusoidal dilatation, atrophy of hepatocytes and&#x0002f;or hepatocytic necrosis (49 <italic>vs</italic> 25&#x00025;, <italic>P</italic>&#x0003d;0.005) and increased morbidity, it did not appear to be linked to increased postoperative mortality in those patients who were resected. It is now generally accepted that provided patients are not overtreated with chemotherapy prior to surgery, there is little evidence of increased mortality and morbidity.</p><p>Ideally, the overall survival benefit conferred by neoadjuvant treatment needs to be validated in a prospective randomised trial in the palliative setting. Such a trial, in the light of present knowledge, would be ethically unacceptable because it should include a no surgery arm in which patients would not undergo surgery, even if their liver metastases become resectable after chemotherapy. However, prolonged (5 years or more) follow-up of patients, with identification of the particular regimen used to facilitate the resection of liver metastases, may be all that is necessary to fully evaluate the benefits of the different neoadjuvant treatment choices.</p><p>What is clear from the results of the current study is that irinotecan combination therapy (FOLFIRI) should be considered for the neoadjuvant treatment of patients with mCRC who have unresectable liver metastases as part of current strategic patient management practices. Future large-scale randomised studies in this setting should therefore include, for comparison, arms that receive irinotecan-based chemotherapy. Additionally, conventional chemotherapy could be combined with one or more molecularly targeted drugs as soon as the data on their role in advanced disease become available (<xref ref-type="other" rid="bib29">Van Cutsem <italic>et al</italic>, 2007</xref>).</p></sec></body><back><ack><p>No financial support was received for this independent study. However, editorial assistance was provided by Cancer Communications and supported by Pfizer.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name></person-group><article-title>Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>ii13</fpage><lpage>ii16</lpage><!--PubMed citation query: 'Ann Oncol||14|ii13||bib1|'--><pub-id pub-id-type="pmid">12810452</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>Pascal</surname><given-names>G</given-names></name><name><surname>Valeanu</surname><given-names>A</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>Paule</surname><given-names>B</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Ghemard</surname><given-names>O</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name></person-group><article-title>Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival</article-title><source>Ann Surg</source><year>2004a</year><volume>240</volume><fpage>644</fpage><lpage>657</lpage>discussion 657&#x02013;658<!--PubMed citation query: 'Ann Surg||240|644||bib2|'--><pub-id pub-id-type="pmid">15383792</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Pascal</surname><given-names>G</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>Paule</surname><given-names>B</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name></person-group><article-title>Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases</article-title><source>Ann Surg</source><year>2004b</year><volume>240</volume><fpage>1052</fpage><lpage>1061</lpage>discussion 1061&#x02013;1064<!--PubMed citation query: 'Ann Surg||240|1052||bib3|'--><pub-id pub-id-type="pmid">15570210</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Sebagh</surname><given-names>M</given-names></name><name><surname>Plasse</surname><given-names>M</given-names></name><name><surname>Karam</surname><given-names>V</given-names></name><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><name><surname>Bouchahda</surname><given-names>M</given-names></name><name><surname>Jasmin</surname><given-names>C</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name></person-group><article-title>Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM)</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>16S</fpage><!--PubMed citation query: 'J Clin Oncol||23|16S||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>SR</given-names></name><name><surname>Horvath</surname><given-names>WL</given-names></name><name><surname>Sternfeld</surname><given-names>WC</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Dakhil</surname><given-names>SR</given-names></name><name><surname>Levitt</surname><given-names>R</given-names></name><name><surname>Rowland</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Donohue</surname><given-names>JH</given-names></name></person-group><article-title>Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>9243</fpage><lpage>9249</lpage><!--PubMed citation query: 'J Clin Oncol||23|9243||bib5|'--><pub-id pub-id-type="pmid">16230673</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Farabos</surname><given-names>C</given-names></name><name><surname>Waechter</surname><given-names>F</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Majno</surname><given-names>P</given-names></name><name><surname>Engarran</surname><given-names>L</given-names></name></person-group><article-title>Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy</article-title><source>Ann Surg</source><year>1996</year><volume>224</volume><fpage>509</fpage><lpage>520</lpage><!--PubMed citation query: 'Ann Surg||224|509||bib6|'--><pub-id pub-id-type="pmid">8857855</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alakl</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><!--PubMed citation query: 'Lancet||355|1041||bib7|'--><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Brunetti</surname><given-names>IM</given-names></name><name><surname>Pfanner</surname><given-names>E</given-names></name><name><surname>Allegrini</surname><given-names>G</given-names></name><name><surname>Barbara</surname><given-names>C</given-names></name><name><surname>Crino</surname><given-names>L</given-names></name><name><surname>Benedetti</surname><given-names>G</given-names></name></person-group><article-title>Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1670</fpage><lpage>1676</lpage><!--PubMed citation query: 'J Clin Oncol||25|1670||bib8|'--><pub-id pub-id-type="pmid">17470860</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>FG</given-names></name><name><surname>Drebin</surname><given-names>JA</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>Dehdashti</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>BA</given-names></name><name><surname>Strasberg</surname><given-names>SM</given-names></name></person-group><article-title>Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>438</fpage><lpage>447</lpage>discussion 447&#x02013;450<!--PubMed citation query: 'Ann Surg||240|438||bib9|'--><pub-id pub-id-type="pmid">15319715</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>FG</given-names></name><name><surname>Ritter</surname><given-names>J</given-names></name><name><surname>Goodwin</surname><given-names>JW</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>Hawkins</surname><given-names>WG</given-names></name><name><surname>Strasberg</surname><given-names>SM</given-names></name></person-group><article-title>Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases</article-title><source>J Am Coll Surg</source><year>2005</year><volume>200</volume><fpage>845</fpage><lpage>853</lpage><!--PubMed citation query: 'J Am Coll Surg||200|845||bib10|'--><pub-id pub-id-type="pmid">15922194</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Alberts</surname><given-names>S</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name></person-group><article-title>Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1311</fpage><lpage>1319</lpage><!--PubMed citation query: 'Ann Oncol||16|1311||bib11|'--><pub-id pub-id-type="pmid">15870084</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>MP</given-names></name><name><surname>Schoffski</surname><given-names>P</given-names></name><name><surname>Seufferlein</surname><given-names>T</given-names></name><name><surname>Nolting</surname><given-names>A</given-names></name><name><surname>Pollert</surname><given-names>P</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name></person-group><article-title>Cetuximab and irinotecan&#x0002f;5-fluorouracil&#x0002f;folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma</article-title><source>Ann Oncol</source><year>2006</year><volume>17</volume><fpage>450</fpage><lpage>456</lpage><!--PubMed citation query: 'Ann Oncol||17|450||bib12|'--><pub-id pub-id-type="pmid">16303861</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Fortner</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>RL</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><fpage>309</fpage><lpage>318</lpage><!--PubMed citation query: 'Ann Surg||230|309||bib13|'--><pub-id pub-id-type="pmid">10493478</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Alafaci</surname><given-names>E</given-names></name><name><surname>Bertheault-Cvitkovic</surname><given-names>F</given-names></name><name><surname>Jasmin</surname><given-names>C</given-names></name><name><surname>Reynes</surname><given-names>M</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name></person-group><article-title>Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery</article-title><source>Ann Oncol</source><year>1999</year><volume>10</volume><fpage>663</fpage><lpage>669</lpage><!--PubMed citation query: 'Ann Oncol||10|663||bib14|'--><pub-id pub-id-type="pmid">10442188</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>WM</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Yeo</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Koh</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>YY</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Leow</surname><given-names>CK</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the cancer therapeutic research group</article-title><source>Med Oncol</source><year>2005</year><volume>22</volume><fpage>303</fpage><lpage>312</lpage><!--PubMed citation query: 'Med Oncol||22|303||bib15|'--><pub-id pub-id-type="pmid">16110141</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karoui</surname><given-names>M</given-names></name><name><surname>Penna</surname><given-names>C</given-names></name><name><surname>Amin-Hashem</surname><given-names>M</given-names></name><name><surname>Mitry</surname><given-names>E</given-names></name><name><surname>Benoist</surname><given-names>S</given-names></name><name><surname>Franc</surname><given-names>B</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name></person-group><article-title>Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases</article-title><source>Ann Surg</source><year>2006</year><volume>243</volume><fpage>1</fpage><lpage>7</lpage><!--PubMed citation query: 'Ann Surg||243|1||bib16|'--><pub-id pub-id-type="pmid">16371728</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>van Cutsem</surname><given-names>E</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>El-Serafi</surname><given-names>M</given-names></name><name><surname>Lutz</surname><given-names>MP</given-names></name><name><surname>Lorenz</surname><given-names>M</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name><name><surname>Ruckle-Lanz</surname><given-names>H</given-names></name><name><surname>Frickhofen</surname><given-names>N</given-names></name><name><surname>Fuchs</surname><given-names>R</given-names></name><name><surname>Mergenthaler</surname><given-names>HG</given-names></name><name><surname>Langenbuch</surname><given-names>T</given-names></name><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Voigtmann</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Genicot</surname><given-names>B</given-names></name><name><surname>Anak</surname><given-names>O</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name></person-group><article-title>Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>4856</fpage><lpage>4865</lpage><!--PubMed citation query: 'J Clin Oncol||23|4856||bib17|'--><pub-id pub-id-type="pmid">15939923</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Cupini</surname><given-names>S</given-names></name><name><surname>Marcucci</surname><given-names>L</given-names></name><name><surname>Cerri</surname><given-names>E</given-names></name><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Allegrini</surname><given-names>G</given-names></name><name><surname>Brunetti</surname><given-names>IM</given-names></name><name><surname>Pfanner</surname><given-names>E</given-names></name><name><surname>Viti</surname><given-names>M</given-names></name><name><surname>Goletti</surname><given-names>O</given-names></name><name><surname>Filipponi</surname><given-names>F</given-names></name><name><surname>Falcone</surname><given-names>A</given-names></name></person-group><article-title>Treatment with 5-fluorouracil&#x0002f;folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2006</year><volume>13</volume><fpage>58</fpage><lpage>65</lpage><!--PubMed citation query: 'Ann Surg Oncol||13|58||bib18|'--><pub-id pub-id-type="pmid">16372158</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Collette</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Poston</surname><given-names>G</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Bechstein</surname><given-names>W</given-names></name><name><surname>Walpole</surname><given-names>E</given-names></name><name><surname>Gruenberger</surname><given-names>T</given-names></name></person-group><article-title>Final results of the EORTC intergroup randomized phase III study 40983 &#x0005b;EPOC&#x0005d; evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>2S</fpage>abstract LBA 5<!--PubMed citation query: 'J Clin Oncol||25|2S||bib19|'--></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>74</fpage><lpage>108</lpage><!--PubMed citation query: 'CA Cancer J Clin||55|74||bib20|'--><pub-id pub-id-type="pmid">15761078</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Scoggins</surname><given-names>CR</given-names></name><name><surname>Zorzi</surname><given-names>D</given-names></name><name><surname>Abdalla</surname><given-names>EK</given-names></name><name><surname>Andres</surname><given-names>A</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Loyer</surname><given-names>EM</given-names></name><name><surname>Muratore</surname><given-names>A</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Capussotti</surname><given-names>L</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name></person-group><article-title>Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases</article-title><source>Ann Surg</source><year>2005</year><volume>241</volume><fpage>715</fpage><lpage>722</lpage>discussion 722&#x02013;724<!--PubMed citation query: 'Ann Surg||241|715||bib21|'--><pub-id pub-id-type="pmid">15849507</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pozzo</surname><given-names>C</given-names></name><name><surname>Basso</surname><given-names>M</given-names></name><name><surname>Cassano</surname><given-names>A</given-names></name><name><surname>Quirino</surname><given-names>M</given-names></name><name><surname>Schinzari</surname><given-names>G</given-names></name><name><surname>Trigila</surname><given-names>N</given-names></name><name><surname>Vellone</surname><given-names>F</given-names></name><name><surname>Giuliante</surname><given-names>F</given-names></name><name><surname>Nuzzo</surname><given-names>G</given-names></name><name><surname>Barone</surname><given-names>C</given-names></name></person-group><article-title>Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>933</fpage><lpage>939</lpage><!--PubMed citation query: 'Ann Oncol||15|933||bib22|'--><pub-id pub-id-type="pmid">15151951</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Douma</surname><given-names>J</given-names></name><name><surname>Wals</surname><given-names>J</given-names></name><name><surname>Honkoop</surname><given-names>AH</given-names></name><name><surname>Erdkamp</surname><given-names>FL</given-names></name><name><surname>de Jong</surname><given-names>RS</given-names></name><name><surname>Rodenburg</surname><given-names>CJM</given-names></name><name><surname>Mol</surname><given-names>L</given-names></name><name><surname>Antonini</surname><given-names>NF</given-names></name></person-group><article-title>Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>166S</fpage>abstract 4012<!--PubMed citation query: 'J Clin Oncol||25|166S||bib23|'--></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Audard</surname><given-names>V</given-names></name><name><surname>Sartoretti</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Brezault</surname><given-names>C</given-names></name><name><surname>Le Charpentier</surname><given-names>M</given-names></name><name><surname>Dousset</surname><given-names>B</given-names></name><name><surname>Morel</surname><given-names>P</given-names></name><name><surname>Soubrane</surname><given-names>O</given-names></name><name><surname>Chaussade</surname><given-names>S</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Terris</surname><given-names>B</given-names></name></person-group><article-title>Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>460</fpage><lpage>466</lpage><!--PubMed citation query: 'Ann Oncol||15|460||bib24|'--><pub-id pub-id-type="pmid">14998849</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||343|905||bib25|'--><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Topham</surname><given-names>C</given-names></name><name><surname>James</surname><given-names>R</given-names></name><name><surname>Gwyther</surname><given-names>SJ</given-names></name><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Shepherd</surname><given-names>S</given-names></name><name><surname>Maraveyas</surname><given-names>A</given-names></name><name><surname>Ferry</surname><given-names>DR</given-names></name><name><surname>Meade</surname><given-names>AM</given-names></name><name><surname>Thompson</surname><given-names>L</given-names></name><name><surname>Griffiths</surname><given-names>GO</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name><name><surname>Stephens</surname><given-names>RJ</given-names></name><collab>FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group</collab></person-group><article-title>Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>143</fpage><lpage>152</lpage><!--PubMed citation query: 'Lancet||370|143||bib26|'--><pub-id pub-id-type="pmid">17630037</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thirion</surname><given-names>P</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name><name><surname>Pignon</surname><given-names>JP</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Braud</surname><given-names>AC</given-names></name><name><surname>Carlson</surname><given-names>RW</given-names></name><name><surname>O'Connell</surname><given-names>M</given-names></name><name><surname>Sargent</surname><given-names>P</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name></person-group><article-title>Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3766</fpage><lpage>3775</lpage><!--PubMed citation query: 'J Clin Oncol||22|3766||bib27|'--><pub-id pub-id-type="pmid">15365073</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Achille</surname><given-names>E</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Flesh</surname><given-names>M</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name><name><surname>Quinaux</surname><given-names>E</given-names></name><name><surname>Couteau</surname><given-names>C</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Colin</surname><given-names>P</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name></person-group><article-title>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>229</fpage><lpage>237</lpage><!--PubMed citation query: 'J Clin Oncol||22|229||bib28|'--><pub-id pub-id-type="pmid">14657227</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Nowacki</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Shchepotin</surname><given-names>I</given-names></name><name><surname>Maurel</surname><given-names>J</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Nippgen</surname><given-names>J</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C</given-names></name></person-group><article-title>Randomized phase III study of irinotecan and 5-FU&#x0002f;FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>164S</fpage>abstract 4000<!--PubMed citation query: 'J Clin Oncol||25|164S||bib29|'--></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>EJ</given-names></name><name><surname>Oliveira</surname><given-names>J</given-names></name><name><surname>Kataja</surname><given-names>VV</given-names></name></person-group><article-title>ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><supplement>Suppl 1</supplement><fpage>i18</fpage><lpage>i19</lpage><!--PubMed citation query: 'Ann Oncol||16|i18||bib30|'--><pub-id pub-id-type="pmid">15888738</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaniboni</surname><given-names>A</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><name><surname>Tinazzi</surname><given-names>A</given-names></name><name><surname>Codignola</surname><given-names>C</given-names></name><name><surname>Faggiuolo</surname><given-names>R</given-names></name><name><surname>Sperti</surname><given-names>E</given-names></name></person-group><article-title>Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey</article-title><source>Tumori</source><year>2005</year><volume>91</volume><fpage>383</fpage><lpage>387</lpage><!--PubMed citation query: 'Tumori||91|383||bib31|'--><pub-id pub-id-type="pmid">16459633</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>(<bold>A</bold>) Median overall survival. (<bold>B</bold>) Median disease-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6603988f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Baseline characteristics of patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristic</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>n</italic>&#x0003d;40 patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Gender</italic> (&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="." charoff="50">60</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="." charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Median age, years (range)</td><td align="char" valign="top" char="." charoff="50">58.7 (32&#x02013;75)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>ECOG performance status</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="." charoff="50">97.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1&#x02013;2</td><td align="char" valign="top" char="." charoff="50">2.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Metastases</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Synchronous</td><td align="char" valign="top" char="." charoff="50">67.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Metachronous</td><td align="char" valign="top" char="." charoff="50">32.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Number of metastases</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;3</td><td align="char" valign="top" char="." charoff="50">52.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3&#x02013;6</td><td align="char" valign="top" char="." charoff="50">20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;6</td><td align="char" valign="top" char="." charoff="50">27.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Largest metastasis</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;5&#x02009;cm diameter</td><td align="char" valign="top" char="." charoff="50">30</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;5&#x02009;cm diameter</td><td align="char" valign="top" char="." charoff="50">70</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Site of metastasis</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hilum</td><td align="char" valign="top" char="." charoff="50">17.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Other sites</td><td align="char" valign="top" char="." charoff="50">82.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Main cause of unresectability</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Number of metastases</td><td align="char" valign="top" char="." charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Location of metastases</td><td align="char" valign="top" char="." charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Size of metastasis</td><td align="char" valign="top" char="." charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Insufficient liver reserve</td><td align="char" valign="top" char="." charoff="50">5</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>ECOG&#x0003d;Eastern Cooperative Oncology Group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Survival and time to progression in resected and non-resected patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>All patients <italic>n</italic>&#x0003d;40</bold></th><th align="center" valign="top" charoff="50"><bold>Non-resected patients <italic>n</italic>&#x0003d;27</bold></th><th align="center" valign="top" charoff="50"><bold>Resected patients <italic>n</italic>&#x0003d;13</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Median survival, months (range)</td><td align="center" valign="top" charoff="50">31.5 (4&#x02013;92)</td><td align="center" valign="top" charoff="50">24</td><td align="center" valign="top" charoff="50">NR</td></tr><tr><td align="left" valign="top" charoff="50">Median TTP, months (range)</td><td align="center" valign="top" charoff="50">14.3 (2&#x02013;49)</td><td align="center" valign="top" charoff="50">5.2 (2&#x02013;13)</td><td align="center" valign="top" charoff="50">52.5</td></tr><tr><td align="left" valign="top" charoff="50">Median DF survival, months (range)</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">52.5 (2&#x02013;89)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Survival</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;6 months</td><td align="center" valign="top" charoff="50">97.5</td><td align="center" valign="top" charoff="50">96.2</td><td align="center" valign="top" charoff="50">100 (85&#x00025; DF)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1-year follow-up</td><td align="center" valign="top" charoff="50">87.5</td><td align="center" valign="top" charoff="50">81.4</td><td align="center" valign="top" charoff="50">100 (77&#x00025; DF)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2-year follow-up</td><td align="center" valign="top" charoff="50">63.5</td><td align="center" valign="top" charoff="50">55.5</td><td align="center" valign="top" charoff="50">100 (62&#x00025; DF)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Last follow-up (5 years)</td><td align="center" valign="top" charoff="50">22.5</td><td align="center" valign="top" charoff="50">3.7</td><td align="center" valign="top" charoff="50">62 (46&#x00025; DF)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">(95&#x00025; CI: 10.5, 34.5)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">(OS 95&#x00025; CI: 19.3, 72.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">(DF 95&#x00025; CI: 19.3, 72.9)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>CI&#x0003d;confidence interval; DF, disease-free; NR&#x0003d;not reached; OS&#x0003d;overall survival; TTP&#x0003d;time to progression.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


